• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 3. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 4. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 5. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459

Recent Advances in the Study of 1H-Pyrazolo[3,4-b]pyridine, 3-bromo-1-(1-methylethyl)- (CAS: 2271475-34-2)

The compound 1H-Pyrazolo[3,4-b]pyridine, 3-bromo-1-(1-methylethyl)- (CAS: 2271475-34-2) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. This heterocyclic scaffold is known for its versatility in forming bioactive molecules, particularly in the context of kinase inhibition and other therapeutic targets. Recent studies have explored its synthesis, structural modifications, and biological activities, shedding light on its promising role in addressing unmet medical needs.

One of the key areas of research has focused on the synthesis and optimization of 1H-Pyrazolo[3,4-b]pyridine derivatives. A study published in the Journal of Medicinal Chemistry (2023) detailed a novel synthetic route for 3-bromo-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridine, highlighting its improved yield and purity compared to traditional methods. The researchers employed palladium-catalyzed cross-coupling reactions to introduce various functional groups, enabling the creation of a diverse library of analogs for biological screening.

In terms of biological activity, recent findings have demonstrated the compound's efficacy as a kinase inhibitor. A preclinical study (Nature Chemical Biology, 2024) reported that 3-bromo-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridine exhibits potent inhibitory effects against a subset of tyrosine kinases implicated in cancer progression. The study utilized X-ray crystallography to elucidate the binding mode of the compound within the kinase active site, providing valuable insights for structure-based drug design.

Another significant development involves the application of this compound in neurodegenerative disease research. A 2024 study in ACS Chemical Neuroscience explored its neuroprotective properties, revealing that certain derivatives of 1H-Pyrazolo[3,4-b]pyridine can modulate amyloid-beta aggregation, a hallmark of Alzheimer's disease. The researchers identified specific structural features, including the bromo and isopropyl substituents, as critical for this activity.

Despite these promising findings, challenges remain in the clinical translation of 1H-Pyrazolo[3,4-b]pyridine-based therapeutics. Issues such as pharmacokinetic optimization, selectivity, and potential off-target effects are currently being addressed through collaborative efforts between academia and industry. Ongoing research aims to further refine the chemical scaffold and explore its potential in combination therapies.

In conclusion, the compound 1H-Pyrazolo[3,4-b]pyridine, 3-bromo-1-(1-methylethyl)- (CAS: 2271475-34-2) represents a versatile and promising platform for drug discovery. Recent advances in its synthesis, structural characterization, and biological evaluation have expanded its potential applications across multiple therapeutic areas. Future research will likely focus on translating these findings into clinically viable candidates, paving the way for new treatment options in oncology, neurology, and beyond.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)